Rapid vs Standard Induction to Injectable Extended-Release Buprenorphine: A Randomized Clinical Trial.

ABSTRACT:

Importance

Standard induction (SI) using transmucosal buprenorphine-naloxone is challenging in individuals who inject opioids, use high doses of opioids, or use synthetic opioids (eg, fentanyl).

Objective

To compare the effectiveness and safety of rapid induction (RI; single 4-mg dose of buprenorphine-naloxone) vs SI (≥7 days of buprenorphine-naloxone) followed by extended-release buprenorphine injection.

Design, setting, and participants

This multicenter, open-label randomized clinical trial was conducted from October 26, 2021, to January 19, 2024, at 28 outpatient treatment centers in the US and Canada. Treatment-seeking participants with moderate or severe opioid use disorder who inject opioids, use high doses of opioids, or use fentanyl were studied.

Interventi

SUBMITTER: Shiwach R 

PROVIDER: S-EPMC12522003 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature